Biliary cancer

Intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: Classification and therapeutic implications

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Biliary cancers (BCs) are a diverse group of tumors that arise from the bile duct epithelium and are divided into cholangiocarcinomas of the intrahepatic and extrahepatic cholangiocarcinoma (EHCC) and cancer of the gallbladder. Despite improvements in treatment and diagnosis, BCs are often diagnosed at an advanced stage and associated with poor prognosis and limited treatment options. Recent discoveries have allowed us to have a better understanding of the genomic diversity in BC, and identify genes that are likely contributing to its pathogenesis, proliferation and treatment resistance. Additionally, these advances have allowed us to reason that each anatomic group within BC behave as distinct diseases, with differences in prognosis and outcomes. Based on this knowledge, recent advances have allowed us to identify actionable mutations that form rational therapeutic targets with novel agents, where their relevance will be better understood through the completion of prospective clinical trials.

Original languageEnglish (US)
Pages (from-to)239-301
Number of pages63
JournalJournal of Gastrointestinal Oncology
Volume8
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Biliary Tract Neoplasms
Gallbladder Neoplasms
Cholangiocarcinoma
Neoplasm Genes
Therapeutics
Bile Ducts
Epithelium
Clinical Trials
Mutation
Neoplasms

Keywords

  • Biliary cancers (BCs)
  • Next generation sequencing
  • Targetable mutations

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

@article{28cdcecc40264f72abc5cda6e2587272,
title = "Biliary cancer: Intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: Classification and therapeutic implications",
abstract = "Biliary cancers (BCs) are a diverse group of tumors that arise from the bile duct epithelium and are divided into cholangiocarcinomas of the intrahepatic and extrahepatic cholangiocarcinoma (EHCC) and cancer of the gallbladder. Despite improvements in treatment and diagnosis, BCs are often diagnosed at an advanced stage and associated with poor prognosis and limited treatment options. Recent discoveries have allowed us to have a better understanding of the genomic diversity in BC, and identify genes that are likely contributing to its pathogenesis, proliferation and treatment resistance. Additionally, these advances have allowed us to reason that each anatomic group within BC behave as distinct diseases, with differences in prognosis and outcomes. Based on this knowledge, recent advances have allowed us to identify actionable mutations that form rational therapeutic targets with novel agents, where their relevance will be better understood through the completion of prospective clinical trials.",
keywords = "Biliary cancers (BCs), Next generation sequencing, Targetable mutations",
author = "Daniel Ahn and Tanios Bekaii-Saab",
year = "2017",
month = "4",
day = "1",
doi = "10.21037/jgo.2016.10.01",
language = "English (US)",
volume = "8",
pages = "239--301",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "2",

}

TY - JOUR

T1 - Biliary cancer

T2 - Intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: Classification and therapeutic implications

AU - Ahn, Daniel

AU - Bekaii-Saab, Tanios

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Biliary cancers (BCs) are a diverse group of tumors that arise from the bile duct epithelium and are divided into cholangiocarcinomas of the intrahepatic and extrahepatic cholangiocarcinoma (EHCC) and cancer of the gallbladder. Despite improvements in treatment and diagnosis, BCs are often diagnosed at an advanced stage and associated with poor prognosis and limited treatment options. Recent discoveries have allowed us to have a better understanding of the genomic diversity in BC, and identify genes that are likely contributing to its pathogenesis, proliferation and treatment resistance. Additionally, these advances have allowed us to reason that each anatomic group within BC behave as distinct diseases, with differences in prognosis and outcomes. Based on this knowledge, recent advances have allowed us to identify actionable mutations that form rational therapeutic targets with novel agents, where their relevance will be better understood through the completion of prospective clinical trials.

AB - Biliary cancers (BCs) are a diverse group of tumors that arise from the bile duct epithelium and are divided into cholangiocarcinomas of the intrahepatic and extrahepatic cholangiocarcinoma (EHCC) and cancer of the gallbladder. Despite improvements in treatment and diagnosis, BCs are often diagnosed at an advanced stage and associated with poor prognosis and limited treatment options. Recent discoveries have allowed us to have a better understanding of the genomic diversity in BC, and identify genes that are likely contributing to its pathogenesis, proliferation and treatment resistance. Additionally, these advances have allowed us to reason that each anatomic group within BC behave as distinct diseases, with differences in prognosis and outcomes. Based on this knowledge, recent advances have allowed us to identify actionable mutations that form rational therapeutic targets with novel agents, where their relevance will be better understood through the completion of prospective clinical trials.

KW - Biliary cancers (BCs)

KW - Next generation sequencing

KW - Targetable mutations

UR - http://www.scopus.com/inward/record.url?scp=85017577495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017577495&partnerID=8YFLogxK

U2 - 10.21037/jgo.2016.10.01

DO - 10.21037/jgo.2016.10.01

M3 - Review article

VL - 8

SP - 239

EP - 301

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 2

ER -